Myeloma Canada endorses Health Canada's approval of Revlimid

    Revlimid signals new hope for Canadians with bone marrow cancer

    MONTREAL, Oct. 6 /CNW/ - Myeloma Canada endorses Health Canada's decision
to approve Revlimid(R) (lenalidomide), a new treatment for multiple myeloma,
clearly demonstrating their commitment to fighting this incurable form of
cancer. Revlimid is an oral medication that has demonstrated an ability to
extend overall survival of multiple myeloma patients and slow the progression
of the disease for patients who have failed other treatments.
    "Health Canada's approval of Revlimid is welcome news for Canadians
living with multiple myeloma," says Myeloma Canada President John Lemieux.
"Scientific advances in treatments of blood disorders are helping patients
live much longer and have a better quality of life. We are extremely pleased
to hear about this approval as it supports doctors in providing the best
possible care to all patients."

    About Multiple Myeloma

    Multiple myeloma, a cancer of the plasma cell, is an incurable but
treatable disease. The cancer starts in plasma cells, which are made in the
bone marrow, and develop into antibodies that help fight infections. In
myeloma, abnormal plasma cells, called myeloma cells, grow uncontrollably,
crowding out the normal blood cells in the bone. This can bring symptoms such
as fatigue, recurrent infections and pain resulting from bone fractures, which
disturb the body's balance of minerals and prevent other organs, such as the
kidney and nerves, from working properly. In Canada, approximately 2,000
people are diagnosed with multiple myeloma every year.

    Myeloma Canada

    Myeloma Canada is a non-profit organization, with registered charity
status dedicated to supporting people living with multiple myeloma and is the
only national organization exclusively devoted to the Canadian myeloma
community. The mission of Myeloma Canada is to: provide educational resources
and support to patients, families, and caregivers; increase awareness of the
disease; and promote improved access to new therapies, treatment options, and
health care resources. Myeloma Canada works with regional support groups and
key myeloma experts to strengthen the voice of the Canadian myeloma community.
Myeloma Canada works in close affiliation with the International Myeloma
Foundation, the world's oldest and largest myeloma organization. For more
information or to find out how you can help please visit our website at

For further information:

For further information: Media Contact: Sylvie Lafrance, (514) 472-0372,

Organization Profile

Myeloma Canada

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890